These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9702935)

  • 21. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.
    Hallberg P; Karlsson J; Kurland L; Lind L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Melhus H
    J Hypertens; 2002 Oct; 20(10):2089-93. PubMed ID: 12359989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
    Dahlof B; Zanchetti A; Diez J; Nicholls MG; Yu CM; Barrios V; Aurup P; Smith RD; Johansson M;
    J Hypertens; 2002 Sep; 20(9):1855-64. PubMed ID: 12195129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators.
    Oparil S; Guthrie R; Lewin AJ; Marbury T; Reilly K; Triscari J; Witcher JA
    Clin Ther; 1998; 20(3):398-409. PubMed ID: 9663357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension.
    Neutel JM; Franklin SS; Lapuerta P; Bhaumik A; Ptaszynska A
    J Hum Hypertens; 2008 Apr; 22(4):266-74. PubMed ID: 17928878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy of felodipine ER on regression of left ventricular hypertrophy in patients with primary hypertension.
    Nalbantgil I; Onder R; Killiçcioglu B; Boydak B; Terzioglu E; Yilmaz H
    Blood Press; 1996 Sep; 5(5):285-91. PubMed ID: 8879601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.
    Kurland L; Liljedahl U; Karlsson J; Kahan T; Malmqvist K; Melhus H; Syvänen AC; Lind L
    Am J Hypertens; 2004 Jan; 17(1):8-13. PubMed ID: 14700505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adipocyte-derived leucine aminopeptidase genotype and response to antihypertensive therapy.
    Hallberg P; Lind L; Michaëlsson K; Kurland L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Liljedahl U; Syvänen AC; Melhus H
    BMC Cardiovasc Disord; 2003 Sep; 3():11. PubMed ID: 13678427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.
    Neutel JM; Germino FW; Smith D
    J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):84-9. PubMed ID: 16470487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension.
    Stumpe KO; Haworth D; Hoglund C; Kerwin L; Martin A; Simon T; Masson C; Kassler-Taub K; Osbakken M
    Blood Press; 1998 Jan; 7(1):31-7. PubMed ID: 9551875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
    Müller-Brunotte R; Kahan T; López B; Edner M; González A; Díez J; Malmqvist K
    J Hypertens; 2007 Sep; 25(9):1958-66. PubMed ID: 17762662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of irbesartan on left ventricular mass and arterial stiffness in hypertensive patients.
    Park CG; Ahn JC; Hong SJ; Kim EJ; Lee SJ; Park SM; Seo HS; Oh DJ
    Korean J Intern Med; 2006 Jun; 21(2):103-8. PubMed ID: 16913439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension.
    Huang QF; Sheng CS; Li Y; Ma GS; Dai QY; Wang JG;
    Drugs R D; 2013 Jun; 13(2):109-17. PubMed ID: 23605903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy.
    Gaudio C; Ferri FM; Giovannini M; Pannarale G; Puddu PE; Vittore A; Fera MS; Vizza CD; Fedele F
    J Cardiovasc Pharmacol; 2003 Nov; 42(5):622-8. PubMed ID: 14576510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One-year study of felodipine or placebo for stage 1 isolated systolic hypertension.
    Black HR; Elliott WJ; Weber MA; Frishman WH; Strom JA; Liebson PR; Hwang CT; Ruff DA; Montoro R; DeQuattro V; Zhang D; Schleman MM; Klibaner MI
    Hypertension; 2001 Nov; 38(5):1118-23. PubMed ID: 11711508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term safety and antihypertensive efficacy of irbesartan: pooled results of five open-label studies.
    Littlejohn T; Saini R; Kassler-Taub K; Chrysant SG; Marbury T
    Clin Exp Hypertens; 1999 Nov; 21(8):1273-95. PubMed ID: 10574413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antihypertensive treatment in hypertensive patients with normal left ventricular mass is associated with left ventricular remodeling and improved diastolic function.
    Schulman DS; Flores AR; Tugoen J; Dianzumba S; Reichek N
    Am J Cardiol; 1996 Jul; 78(1):56-60. PubMed ID: 8712119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension.
    Chan JC; Critchley JA; Lappe JT; Raskin SJ; Snavely D; Goldberg AI; Sweet CS
    J Hum Hypertens; 1995 Sep; 9(9):765-71. PubMed ID: 8551492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential effects of felodipine and nifedipine on 24-h blood pressure and left ventricular mass.
    Myers MG; Leenen FH; Tanner J
    Am J Hypertens; 1995 Jul; 8(7):712-8. PubMed ID: 7546497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
    Rodby RA; Rohde RD; Clarke WR; Hunsicker LG; Anzalone DA; Atkins RC; Ritz E; Lewis EJ
    Nephrol Dial Transplant; 2000 Apr; 15(4):487-97. PubMed ID: 10727543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with rilmenidine: a double-blind, randomized, controlled (versus nifedipine) study.
    Sadowski Z; Szwed H; Kuch-Wocial A; Kubasik A; Januszewicz W; Krupa-Wojciechowska B; Polak G; Stejfa M; Dvorak I; Balazovjech I; Dubai G; Simon K
    J Hypertens Suppl; 1998 Aug; 16(3):S55-62. PubMed ID: 9747912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.